Shots:

• Exscientia to get up to $266.2M including upfront- research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration  
• The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for the identification of therapies for cardiovascular and oncological diseases
• Exscientia’s AI-driven drug discovery platform providing novel chemical matter for targets and enables identification of therapies

Click here to read full press release/ article | Ref: Bayer | Image: Behance